{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:55:56Z","timestamp":1790229356852,"version":"4.1.0"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,2,16]],"date-time":"2013-02-16T00:00:00Z","timestamp":1360972800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s00259-013-2342-x","type":"journal-article","created":{"date-parts":[[2013,2,15]],"date-time":"2013-02-15T17:10:29Z","timestamp":1360948229000},"page":"943-966","source":"Crossref","is-referenced-by-count":106,"title":["18F-Fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type"],"prefix":"10.1007","volume":"40","author":[{"given":"Sona","family":"Balogova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-No\u00ebl","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Nataf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Michaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Huchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaldoun","family":"Kerrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Montravers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,2,16]]},"reference":[{"key":"2342_CR1","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1677\/erc.1.01017","volume":"12","author":"F Panzuto","year":"2005","unstructured":"Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005;12:1083\u201392.","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"2342_CR2","first-page":"1602","volume":"40","author":"R Lebtahi","year":"1999","unstructured":"Lebtahi R, Cadiot G, Delahaye N, Genin R, Daou D, Peker MC, et al. Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy. J Nucl Med 1999;40(10):1602\u20138.","journal-title":"J Nucl Med"},{"issue":"6","key":"2342_CR3","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1530\/eje.0.1310577","volume":"131","author":"ET Janson","year":"1994","unstructured":"Janson ET, Westlin JE, Eriksson B, Ahlstr\u00f6m H, Nilsson S, \u00d6berg K. [111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. Eur J Endocrinol 1994;131(6):577\u201381.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2342_CR4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s002590050197","volume":"25","author":"S Adams","year":"1998","unstructured":"Adams S, Baum R, Rink T, Schumm-Dr\u00e4ger PM, Usadel KH, H\u00f6r G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998;25(1):79\u201383.","journal-title":"Eur J Nucl Med"},{"key":"2342_CR5","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s002689900439","volume":"22","author":"C Pasquali","year":"1998","unstructured":"Pasquali C, Rubello D, Sperti C, Gasparoni P, Liessi G, Chierichetti F, et al. Neuroendocrine tumour imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior. World J Surg 1998;22:588\u201392.","journal-title":"World J Surg"},{"issue":"5","key":"2342_CR6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/17.5.303","volume":"17","author":"AG Pearse","year":"1969","unstructured":"Pearse AG. The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. J Histochem Cytochem 1969;17(5):303\u20138.","journal-title":"J Histochem Cytochem"},{"issue":"1","key":"2342_CR7","first-page":"32","volume":"37","author":"M Bergstr\u00f6m","year":"1996","unstructured":"Bergstr\u00f6m M, Eriksson B, \u00d6berg K, Sundin A, Ahlstr\u00f6m H, Lindner KJ, et al. In vivo demonstration of enzyme activity in endocrine pancreatic tumors: decarboxylation of carbon-11-DOPA to carbon-11-dopamine. J Nucl Med 1996;37(1):32\u20137.","journal-title":"J Nucl Med"},{"issue":"Suppl 1","key":"2342_CR8","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1007\/s00259-011-2013-8","volume":"39","author":"JB Bomanji","year":"2012","unstructured":"Bomanji JB, Papathanasiou ND. 111In-DTPA0-octreotide (Octreoscan), 131I-MIBG and other agents for radionuclide therapy of NETs. Eur J Nucl Med Mol Imaging 2012;39 Suppl 1:S113\u201325.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"2342_CR9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.beem.2004.11.001","volume":"19","author":"B Eriksson","year":"2005","unstructured":"Eriksson B, \u00d6rlefors H, Oberg K, Sundin A, Bergstr\u00f6m M, L\u00e5ngstr\u00f6m B. Developments in PET for the detection of endocrine tumours. Best Pract Res Clin Endocrinol Metab 2005;19(2):311\u201324.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2342_CR10","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.2967\/jnumed.107.042721","volume":"48","author":"HJ Timmers","year":"2007","unstructured":"Timmers HJ, Hadi M, Carrasquillo JA, Chen CC, Martiniova L, Whatley M, et al. The effects of carbidopa on uptake of 6-18F-fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J Nucl Med 2007;48:1599\u2013606.","journal-title":"J Nucl Med"},{"key":"2342_CR11","first-page":"560","volume":"46","author":"MJ Ribeiro","year":"2005","unstructured":"Ribeiro MJ, De Lonlay P, Delzescaux T, Boddaert N, Jaubert F, Bourgeois S, et al. Characterization of hyperinsulinism in infancy assessed with PET and 18-fluoro-L-DOPA. J Nucl Med 2005;46:560\u20136.","journal-title":"J Nucl Med"},{"key":"2342_CR12","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1200\/JCO.2008.18.8581","volume":"26","author":"S Kauhanen","year":"2008","unstructured":"Kauhanen S, Sepp\u00e4nen M, Nuutila P. Premedication with carbidopa masks positive finding of insulinoma and beta-cell hyperplasia in [(18)F]-dihydroxy-phenyl-alanine positron emission tomography. J Clin Oncol 2008;26:5307\u20138.","journal-title":"J Clin Oncol"},{"key":"2342_CR13","first-page":"1161","volume":"45","author":"A Becherer","year":"2004","unstructured":"Becherer A, Szab\u00f3 M, Karanikas G, Wunderbaldinger P, Angelberger P, Raderer M, et al. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. J Nucl Med 2004;45:1161\u20137.","journal-title":"J Nucl Med"},{"issue":"7","key":"2342_CR14","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/MNM.0b013e3283543304","volume":"33","author":"M Soussan","year":"2012","unstructured":"Soussan M, Nataf V, Kerrou K, Grahek D, Pascal O, Talbot JN, et al. Added value of early 18F-FDOPA PET\/CT acquisition time in medullary thyroid cancer. Nucl Med Commun 2012;33(7):775\u20139.","journal-title":"Nucl Med Commun"},{"issue":"2","key":"2342_CR15","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1097\/RLU.0b013e318238f550","volume":"37","author":"M Hentschel","year":"2012","unstructured":"Hentschel M, Rottenburger C, Boedeker CC, Neumann HP, Brink I. Is there an optimal scan time for 6-[F-18]fluoro-L-DOPA PET in pheochromocytomas and paragangliomas? Clin Nucl Med 2012;37(2):e24\u20139.","journal-title":"Clin Nucl Med"},{"issue":"5","key":"2342_CR16","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1089\/thy.2009.0342","volume":"20","author":"M Luster","year":"2010","unstructured":"Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, et al. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography\/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid 2010;20(5):527\u201333.","journal-title":"Thyroid"},{"issue":"3","key":"2342_CR17","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s00259-009-1294-7","volume":"37","author":"M Luster","year":"2010","unstructured":"Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, et al. Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography\/computed tomography (18F-DOPA PET\/CT) for detecting pheochromocytoma. Eur J Nucl Med Mol Imaging 2010;37(3):484\u201393.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"2342_CR18","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2007.15.1126","volume":"26","author":"KP Koopmans","year":"2008","unstructured":"Koopmans KP, Neels OC, Kema IP, Elsinga PH, Sluiter WJ, Vanghillewe K, et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 2008;26(9):1489\u201395.","journal-title":"J Clin Oncol"},{"key":"2342_CR19","doi-asserted-by":"crossref","first-page":"A197","DOI":"10.1055\/s-0038-1625205","volume":"44","author":"A Becherer","year":"2005","unstructured":"Becherer A, Novotny C, Leitha T. An unusual pitfall in 18F-FDOPA-PET. Nuklearmedizin 2005;44:A197. n\u00b023.","journal-title":"Nuklearmedizin"},{"issue":"9","key":"2342_CR20","first-page":"1455","volume":"47","author":"F Montravers","year":"2006","unstructured":"Montravers F, Grahek D, Kerrou K, Ruszniewski P, de Beco V, Aide N, et al. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? J Nucl Med 2006;47(9):1455\u201362.","journal-title":"J Nucl Med"},{"issue":"4","key":"2342_CR21","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1210\/jc.2008-1349","volume":"94","author":"F Montravers","year":"2009","unstructured":"Montravers F, Kerrou K, Nataf V, Huchet V, Lotz JP, Ruszniewski P, et al. Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors. J Clin Endocrinol Metab 2009;94(4):1295\u2013301.","journal-title":"J Clin Endocrinol Metab"},{"key":"2342_CR22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s002590000404","volume":"28","author":"S Hoegerle","year":"2001","unstructured":"Hoegerle S, Altehofer C, Ghanem N, Brink I, Moser E, Nitzsche E. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001;28:64\u201371.","journal-title":"Eur J Nucl Med"},{"issue":"10","key":"2342_CR23","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.acra.2012.05.008","volume":"19","author":"G Treglia","year":"2012","unstructured":"Treglia G, Cocciolillo F, Di Nardo F, Poscia A, de Waure C, Giordano A, et al. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 dihydroxyphenylalanine positron emission tomography: a meta-analysis. Acad Radiol 2012;19(10):1290\u20139.","journal-title":"Acad Radiol"},{"key":"2342_CR24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1053\/j.semnuclmed.2005.09.002","volume":"36","author":"W Langsteger","year":"2006","unstructured":"Langsteger W, Heinisch M, Fogelman I. The role of fluorodeoxyglucose, 18Fdihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med 2006;36:73\u201392.","journal-title":"Semin Nucl Med"},{"issue":"10","key":"2342_CR25","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1007\/s00259-007-0425-2","volume":"34","author":"B Beuthien-Baumann","year":"2007","unstructured":"Beuthien-Baumann B, Strumpf A, Zessin J, Bredow J, Kotzerke J. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2007;34(10):1604\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2342_CR26","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00330-008-1280-7","volume":"19","author":"M Beheshti","year":"2009","unstructured":"Beheshti M, P\u00f6cher S, Vali R, Waldenberger P, Broinger G, Nader M, et al. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur Radiol 2009;19:1425\u201334.","journal-title":"Eur Radiol"},{"key":"2342_CR27","doi-asserted-by":"crossref","first-page":"524","DOI":"10.2967\/jnumed.107.047720","volume":"49","author":"KP Koopmans","year":"2008","unstructured":"Koopmans KP, de Groot JWB, Plukke JTM, de Vries EG, Kema IP, Sluiter WJ, et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med 2008;49:524\u201331.","journal-title":"J Nucl Med"},{"issue":"4","key":"2342_CR28","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ejso.2010.01.001","volume":"36","author":"MC Marzola","year":"2010","unstructured":"Marzola MC, Pelizzo MR, Ferdeghini M, Toniato A, Massaro A, Ambrosini V, et al. Dual PET\/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: comparison with conventional imaging. Eur J Surg Oncol 2010;36(4):414\u201321.","journal-title":"Eur J Surg Oncol"},{"issue":"12","key":"2342_CR29","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.2967\/jnumed.111.094771","volume":"52","author":"S Kauhanen","year":"2011","unstructured":"Kauhanen S, Schalin-J\u00e4ntti C, Sepp\u00e4nen M, Kajander S, Virtanen S, Schildt J, et al. Complementary roles of 18F-DOPA PET\/CT and 18F-FDG PET\/CT in medullary thyroid cancer. J Nucl Med 2011;52(12):1855\u201363.","journal-title":"J Nucl Med"},{"issue":"12","key":"2342_CR30","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.2967\/jnumed.112.105940","volume":"53","author":"HH Verbeek","year":"2012","unstructured":"Verbeek HH, Plukker JT, Koopmans KP, de Groot JW, Hofstra RM, Muller Kobold AC, et al. Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma. J Nucl Med 2012;53(12):1863\u201371.","journal-title":"J Nucl Med"},{"issue":"5","key":"2342_CR31","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s11307-009-0276-2","volume":"12","author":"TV Bogsrud","year":"2010","unstructured":"Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Kasperbauer JL, et al. The prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma. Mol Imaging Biol 2010;12(5):547\u201353.","journal-title":"Mol Imaging Biol"},{"issue":"4","key":"2342_CR32","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00259-011-2031-6","volume":"39","author":"G Treglia","year":"2012","unstructured":"Treglia G, Castaldi P, Villani MF, Perotti G, de Waure C, Filice A, et al. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET\/CT in patients with recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2012;39(4):569\u201380.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"2342_CR33","first-page":"383","volume":"30","author":"F Montravers","year":"2006","unstructured":"Montravers F, Grahek D, Kerrou K, Gutman F, Leverger G, Talbot J. Impact de la TEP \u00e0 la fluoro-(18F)-dihydroxyph\u00e9nylalanine (FDOPA) sur l\u2019attitude th\u00e9rapeutique en cas de tumeur endocrine: tumeur digestive, cancer m\u00e9dullaire de la thyro\u00efde ou ph\u00e9ochromocytome. Med Nucl 2006;30(7):383\u20139.","journal-title":"Med Nucl"},{"issue":"1","key":"2342_CR34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00259-009-1204-z","volume":"37","author":"BG Conry","year":"2010","unstructured":"Conry BG, Papathanasiou ND, Prakash V, Kayani I, Caplin M, Mahmood S, et al. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET\/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2010;37(1):49\u201357.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"2342_CR35","first-page":"507","volume":"61","author":"I Pa\u0142yga","year":"2010","unstructured":"Pa\u0142yga I, Kowalska A, G\u0105sior-Perczak D, Tarnawska-Pier\u015bci\u0144ska M, S\u0142uszniak J, Sygut J, et al. The role of PET-CT scan with somatostatin analogue labelled with gallium-68 (68Ga-DOTA-TATE PET-CT) in diagnosing patients with disseminated medullary thyroid carcinoma (MTC). Endokrynol Pol 2010;61(5):507\u201311.","journal-title":"Endokrynol Pol"},{"issue":"1","key":"2342_CR36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5603\/NMR.2011.0004","volume":"14","author":"G \u0141api\u0144ska","year":"2011","unstructured":"\u0141api\u0144ska G, Bryszewska M, Fijo\u0142ek-Warszewska A, Koz\u0142owicz-Gudzi\u0144ska I, Ochman P, Sackiewicz-S\u0142aby A. The diagnostic role of 68Ga-DOTATATE PET\/CT in the detection of neuroendocrine tumours. Nucl Med Rev Cent East Eur 2011;14(1):16\u201320.","journal-title":"Nucl Med Rev Cent East Eur"},{"issue":"11","key":"2342_CR37","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s002590100614","volume":"28","author":"M Diehl","year":"2001","unstructured":"Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 2001;28(11):1671\u20136.","journal-title":"Eur J Nucl Med"},{"issue":"1","key":"2342_CR38","first-page":"66","volume":"43","author":"S Szak\u00e1ll Jr","year":"2002","unstructured":"Szak\u00e1ll Jr S, Esik O, Bajzik G, Repa I, Dabasi G, Sinkovics I, et al. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 2002;43(1):66\u201371.","journal-title":"J Nucl Med"},{"issue":"8","key":"2342_CR39","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1245\/ASO.2004.10.015","volume":"11","author":"JW Groot De","year":"2004","unstructured":"De Groot JW, Links TP, Jager PL, Kahraman T, Plukker JT. Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 2004;11(8):786\u201394.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"2342_CR40","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/00006231-200405000-00003","volume":"25","author":"M Gotthardt","year":"2004","unstructured":"Gotthardt M, Battmann A, H\u00f6ffken H, Schurrat T, Pollum H, Beuter D, et al. 18F-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: a clinical study and an analysis of the literature. Nucl Med Commun 2004;25(5):439\u201343.","journal-title":"Nucl Med Commun"},{"issue":"5","key":"2342_CR41","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ejso.2007.08.005","volume":"34","author":"D Rubello","year":"2008","unstructured":"Rubello D, Rampin L, Nanni C, Banti E, Ferdeghini M, Fanti S, et al. The role of 18F-FDG PET\/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study. Eur J Surg Oncol 2008;34(5):581\u20136.","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"2342_CR42","doi-asserted-by":"crossref","first-page":"E207","DOI":"10.1210\/jc.2011-2766","volume":"97","author":"M Lodish","year":"2012","unstructured":"Lodish M, Dagalakis U, Chen CC, Sinaii N, Whitcomb P, Aikin A, et al. (111)In-octreotide scintigraphy for identification of metastatic medullary thyroid carcinoma in children and adolescents. J Clin Endocrinol Metab 2012;97(2):E207\u201312.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2342_CR43","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1089\/thy.2008.0403","volume":"19","author":"RT Kloos","year":"2009","unstructured":"American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009;19(6):565\u2013612.","journal-title":"Thyroid"},{"issue":"10","key":"2342_CR44","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/BF00168169","volume":"19","author":"A Castagnoli","year":"1992","unstructured":"Castagnoli A, Biti G, De Cristofaro MT, Ferri P, Magrini SM, Papi MG, et al. Merkel cell carcinoma and iodine-131 metaiodobenzylguanidine scan. Eur J Nucl Med 1992;19(10):913\u20136.","journal-title":"Eur J Nucl Med"},{"key":"2342_CR45","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1001\/archderm.1992.01680160102014","volume":"128","author":"DJ Kwekkeboom","year":"1992","unstructured":"Kwekkeboom DJ, Hof AM, Lamberts SWJ, Oei HY, Krenning EP. Somatostatin receptor scintigraphy. A simple and sensitive method for the in vivo visualization of Merkel cell tumors and their metastases. Arch Dermatol 1992;128:818\u201321.","journal-title":"Arch Dermatol"},{"key":"2342_CR46","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S1095-0397(00)00038-8","volume":"3","author":"CO Wong","year":"2000","unstructured":"Wong CO, Pham AN, Dworkin HJ. F-18 FDG accumulation in an octreotide negative Merkel cell tumor. Clin Positron Imaging 2000;3:71\u20133.","journal-title":"Clin Positron Imaging"},{"issue":"4","key":"2342_CR47","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11307-005-0006-3","volume":"7","author":"JN Talbot","year":"2005","unstructured":"Talbot JN, Kerrou K, Missoum F, Grahek D, Aide N, Lumbroso J, et al. 6-[F-18]Fluoro-L-DOPA positron emission tomography in the imaging of Merkel cell carcinoma: preliminary report of three cases with 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography or pentetreotide-(111In) SPECT data. Mol Imaging Biol 2005;7(4):257\u201361.","journal-title":"Mol Imaging Biol"},{"issue":"2","key":"2342_CR48","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ejrad.2008.10.032","volume":"73","author":"P Peloschek","year":"2010","unstructured":"Peloschek P, Novotny C, Mueller-Mang C, Weber M, Sailer J, Dawid M, et al. Diagnostic imaging in Merkel cell carcinoma: lessons to learn from 16 cases with correlation of sonography, CT, MRI and PET. Eur J Radiol 2010;73(2):317\u201323.","journal-title":"Eur J Radiol"},{"issue":"6","key":"2342_CR49","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jaad.2012.03.018","volume":"67","author":"MB Colgan","year":"2012","unstructured":"Colgan MB, Tarantola TI, Weaver AL, Wiseman GA, Roenigk RK, Brewer JD, et al. The predictive value of imaging studies in evaluating regional lymph node involvement in Merkel cell carcinoma. J Am Acad Dermatol 2012;67(6):1250\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2342_CR50","first-page":"135","volume":"8","author":"H Golan","year":"2005","unstructured":"Golan H, Volkov O, Linchinsky O, Melloul M. FDG-PET imaging in Merkel cell carcinoma - value of head-to-toe scan. Nucl Med Rev Cent East Eur 2005;8(2):135\u20136.","journal-title":"Nucl Med Rev Cent East Eur"},{"issue":"8","key":"2342_CR51","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/RLU.0b013e31825ae8e7","volume":"37","author":"Y Lu","year":"2012","unstructured":"Lu Y, Fleming SE, Fields RC, Coit DG, Carrasquillo JA. Comparison of 18F-FDG PET\/CT and 111In pentetreotide scan for detection of Merkel cell carcinoma. Clin Nucl Med 2012;37(8):759\u201362.","journal-title":"Clin Nucl Med"},{"issue":"2","key":"2342_CR52","first-page":"347","volume":"16","author":"T Belhocine","year":"2006","unstructured":"Belhocine T, Pierard GE, Fr\u00fchling J, Letesson G, Bolle S, Hustinx R, et al. Clinical added-value of 18FDG PET in neuroendocrine-Merkel cell carcinoma. Oncol Rep 2006;16(2):347\u201352.","journal-title":"Oncol Rep"},{"issue":"3","key":"2342_CR53","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1378\/chest.119.3.950","volume":"119","author":"HP Hauber","year":"2001","unstructured":"Hauber HP, Bohuslaviki KH, Lund CH, Fritscher-Ravens A, Meyer A, Pforte A. Positron emission tomography in the staging of small-cell lung cancer: a preliminary study. Chest 2001;119(3):950\u20134.","journal-title":"Chest"},{"key":"2342_CR54","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1007\/s00259-003-1249-3","volume":"30","author":"T Jacob","year":"2003","unstructured":"Jacob T, Grahek D, Younsi N, Kerrou K, Aide N, Montravers F, et al. Positron emission tomography with [(18)F]FDOPA and [(18)F]FDG in the imaging of small cell lung carcinoma: preliminary results. Eur J Nucl Med Mol Imaging 2003;30:1266\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2342_CR55","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1007\/s00259-004-1606-x","volume":"31","author":"I Brink","year":"2004","unstructured":"Brink I, Schumacher T, Mix M, Ruhland S, Stoelben E, Digel W, et al. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 2004;31:1614\u201320.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2342_CR56","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1210\/jc.2007-1337","volume":"92","author":"S Dubois","year":"2007","unstructured":"Dubois S, Morel O, Rodien P, Illouz F, Girault S, Cahouet A, et al. A pulmonary adrenocorticotropin-secreting carcinoid tumor localized by 6-fluoro-[18F]L-dihydroxyphenylalanine positron emission\/computed tomography imaging in a patient with Cushing\u2019s syndrome. J Clin Endocrinol Metab 2007;92:4512\u20133.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2342_CR57","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00259-008-0769-2","volume":"35","author":"V Ambrosini","year":"2008","unstructured":"Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 2008;35(8):1431\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"2342_CR58","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/MNM.0b013e32832999c1","volume":"30","author":"V Ambrosini","year":"2009","unstructured":"Ambrosini V, Castellucci P, Rubello D, Nanni C, Musto A, Allegri V, et al. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun 2009;30(4):281\u20136.","journal-title":"Nucl Med Commun"},{"key":"2342_CR59","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.2214\/ajr.170.5.9574618","volume":"170","author":"JJ Erasmus","year":"1998","unstructured":"Erasmus JJ, McAdams HP, Patz Jr EF, Coleman RE, Ahuja V, Goodman PC. Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol 1998;170:1369\u201373.","journal-title":"AJR Am J Roentgenol"},{"issue":"6","key":"2342_CR60","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2796.2006.01729.x","volume":"260","author":"S Kr\u00fcger","year":"2006","unstructured":"Kr\u00fcger S, Buck AK, Blumstein NM, Pauls S, Schelzig H, Kropf C, et al. Use of integrated FDG PET\/CT imaging in pulmonary carcinoid tumours. J Intern Med 2006;260(6):545\u201350.","journal-title":"J Intern Med"},{"issue":"1","key":"2342_CR61","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1378\/chest.06-0711","volume":"131","author":"CE Daniels","year":"2007","unstructured":"Daniels CE, Lowe VJ, Aubry MC, Allen MS, Jett JR. The utility of fluorodeoxyglucose emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest 2007;131(1):255\u201360.","journal-title":"Chest"},{"issue":"5","key":"2342_CR62","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2967\/jnumed.109.069765","volume":"51","author":"T Binderup","year":"2010","unstructured":"Binderup T, Knigge U, Loft A, Mortensen J, Pfeifer A, Federspiel B, et al. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med 2010;51(5):704\u201312.","journal-title":"J Nucl Med"},{"issue":"12","key":"2342_CR63","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.2967\/jnumed.109.066639","volume":"50","author":"I Kayani","year":"2009","unstructured":"Kayani I, Conry BG, Groves AM, Win T, Dickson J, Caplin M, et al. A comparison of 68Ga-DOTATATE and 18F-FDG PET\/CT in pulmonary neuroendocrine tumors. J Nucl Med 2009;50(12):1927\u201332.","journal-title":"J Nucl Med"},{"key":"2342_CR64","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1102\/1470-5206.2011.0010","volume":"11","author":"T Jindal","year":"2011","unstructured":"Jindal T, Kumar A, Venkitaraman B, Meena M, Kumar R, Malhotra A, et al. Evaluation of the role of [18F]FDG-PET\/CT and [68Ga]DOTATOC-PET\/CT in differentiating typical and atypical pulmonary carcinoids. Cancer Imaging 2011;11:70\u20135.","journal-title":"Cancer Imaging"},{"key":"2342_CR65","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(63)90951-6","volume":"i","author":"ED Williams","year":"1963","unstructured":"Williams ED, Sandler M. The classification of carcinoid tumours. Lancet 1963;i:238\u20139.","journal-title":"Lancet"},{"key":"2342_CR66","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1210\/jc.86.2.685","volume":"86","author":"E Harst van der","year":"2001","unstructured":"van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, et al. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 2001;86:685\u201393.","journal-title":"J Clin Endocrinol Metab"},{"key":"2342_CR67","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/01.HYP.38.1.6","volume":"38","author":"K Pacak","year":"2001","unstructured":"Pacak K, Eisenhofer G, Carrasquillo JA, Chen CC, Li ST, Goldstein DS. 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 2001;38:6\u20138.","journal-title":"Hypertension"},{"issue":"10","key":"2342_CR68","first-page":"1635","volume":"47","author":"C Franzius","year":"2006","unstructured":"Franzius C, Hermann K, Weckesser M, Kopka K, Juergens KU, Vormoor J, et al. Whole-body PET\/CT with 11C-meta-hydroxyephedrine in tumors of the sympathetic nervous system: feasibility study and comparison with 123I-MIBG SPECT\/CT. J Nucl Med 2006;47(10):1635\u201342.","journal-title":"J Nucl Med"},{"issue":"7","key":"2342_CR69","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1210\/jc.2011-3342","volume":"97","author":"S Yamamoto","year":"2012","unstructured":"Yamamoto S, Hellman P, Wassberg C, Sundin A. 11C-Hydroxyephedrine positron emission tomography imaging of pheochromocytoma: a single center experience over 11\u00a0years. J Clin Endocrinol Metab 2012;97(7):2423\u201332.","journal-title":"J Clin Endocrinol Metab"},{"key":"2342_CR70","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1148\/radiol.2222010622","volume":"222","author":"S Hoegerle","year":"2002","unstructured":"Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I, et al. Pheochromocytomas: detection with 18F DOPA whole body PET\u2014initial results. Radiology 2002;222:507\u201312.","journal-title":"Radiology"},{"key":"2342_CR71","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2967\/jnumed.108.058396","volume":"50","author":"F Imani","year":"2009","unstructured":"Imani F, Agopian VG, Auerbach MS, Walter MA, Imani F, Benz MR, et al. 18F-FDOPA PET and PET\/CT accurately localize pheochromocytomas. J Nucl Med 2009;50:513\u20139.","journal-title":"J Nucl Med"},{"key":"2342_CR72","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1677\/ERC-08-0229","volume":"16","author":"S Kauhanen","year":"2009","unstructured":"Kauhanen S, Sepp\u00e4nen M, Ovaska J, Minn H, Bergman J, Korsoff P, et al. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors. Endocr Relat Cancer 2009;16:255\u201365.","journal-title":"Endocr Relat Cancer"},{"key":"2342_CR73","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00259-003-1115-3","volume":"30","author":"S Hoegerle","year":"2003","unstructured":"Hoegerle S, Ghanem N, Altehoefer C, Schipper J, Brink I, Moser E, et al. 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging 2003;30:689\u201394.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"2342_CR74","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1210\/jc.2009-1054","volume":"94","author":"HB Fiebrich","year":"2009","unstructured":"Fiebrich HB, Brouwers AH, Kerstens MN, Pijl ME, Kema IP, de Jong JR, et al. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab 2009;94(10):3922\u201330.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2342_CR75","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1365-2265.2008.03257.x","volume":"69","author":"D Ta\u00efeb","year":"2008","unstructured":"Ta\u00efeb D, Tessonnier L, Sebag F, Niccoli-Sire P, Morange I, Colavolpe C, et al. The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas. Clin Endocrinol (Oxf) 2008;69(4):580\u20136.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2342_CR76","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2265.2010.03893.x","volume":"74","author":"N Charrier","year":"2011","unstructured":"Charrier N, Deveze A, Fakhry N, Sebag F, Morange I, Gaborit B, et al. Comparison of [111In]pentetreotide-SPECT and [18F]FDOPA-PET in the localization of extra-adrenal paragangliomas: the case for a patient-tailored use of nuclear imaging modalities. Clin Endocrinol (Oxf) 2011;74(1):21\u20139.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2342_CR77","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1210\/jc.2009-2352","volume":"95","author":"C Fottner","year":"2010","unstructured":"Fottner C, Helisch A, Anlauf M, Rossmann H, Musholt TJ, Kreft A, et al. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. J Clin Endocrinol Metab 2010;95(6):2800\u201310.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2342_CR78","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1210\/jc.2011-0333","volume":"96","author":"KS King","year":"2011","unstructured":"King KS, Chen CC, Alexopoulos DK, Whatley MA, Reynolds JC, Patronas N, et al. Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy. J Clin Endocrinol Metab 2011;96(9):2779\u201385.","journal-title":"J Clin Endocrinol Metab"},{"key":"2342_CR79","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/MNM.0b013e328345a340","volume":"32","author":"V Rufini","year":"2011","unstructured":"Rufini V, Treglia G, Castaldi P, Perotti G, Calcagni ML, Corsello SM, et al. Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma. Nucl Med Commun 2011;32:575\u201382.","journal-title":"Nucl Med Commun"},{"issue":"12","key":"2342_CR80","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s00259-012-2215-8","volume":"39","author":"D Ta\u00efeb","year":"2012","unstructured":"Ta\u00efeb D, Timmers HJ, Hindi\u00e9 E, Guillet BA, Neumann HP, Walz MK, et al. EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2012;39(12):1977\u201395.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"2342_CR81","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s00259-012-2087-y","volume":"39","author":"G Treglia","year":"2012","unstructured":"Treglia G, Cocciolillo F, de Waure C, Di Nardo F, Gualano MR, Castaldi P, et al. Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis. Eur J Nucl Med Mol Imaging 2012;39(7):1144\u201353.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"2342_CR82","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1210\/jc.2009-1248","volume":"94","author":"HJ Timmers","year":"2009","unstructured":"Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Havekes B, et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2009;94(12):4757\u201367.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2342_CR83","doi-asserted-by":"crossref","first-page":"E613","DOI":"10.1210\/jc.2011-2626","volume":"97","author":"AB Weisbrod","year":"2012","unstructured":"Weisbrod AB, Kitano M, Gesuwan K, Millo C, Herscovitch P, Nilubol N, et al. Clinical utility of functional imaging with 18F-FDOPA in Von Hippel-Lindau syndrome. J Clin Endocrinol Metab 2012;97(4):E613\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"2342_CR84","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2967\/jnumed.111.101303","volume":"53","author":"HC Rischke","year":"2012","unstructured":"Rischke HC, Benz MR, Wild D, Mix M, Dumont RA, Campbell D, et al. Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET. J Nucl Med 2012;53:1352\u20138.","journal-title":"J Nucl Med"},{"key":"2342_CR85","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1210\/jc.74.5.1082","volume":"74","author":"JC Reubi","year":"1992","unstructured":"Reubi JC, Waser B, Khosla S, Kvols L, Goellner JR, Krenning E, et al. In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 1992;74:1082\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2342_CR86","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1007\/s00259-012-2119-7","volume":"39","author":"JB Maurice","year":"2012","unstructured":"Maurice JB, Troke R, Win Z, Ramachandran R, Al-Nahhas A, Naji M, et al. A comparison of the performance of 68Ga-DOTATATE PET\/CT and 123I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2012;39(8):1266\u201370.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"2342_CR87","first-page":"365","volume":"49","author":"F Montravers","year":"2008","unstructured":"Montravers F, Kerrou K, Huchet V, Nataf V, Talbot JN. Evaluation of the impact of FDOPA-PET on the management of patients referred for pheochromocytoma. J Nucl Med 2008;49(Suppl 1):365.","journal-title":"J Nucl Med"},{"key":"2342_CR88","first-page":"223","volume":"47","author":"S Ezziddin","year":"2006","unstructured":"Ezziddin S, Logvinski T, Yong-Hing C, Ahmadzadehfar H, Fischer HP, Palmedo H, et al. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. J Nucl Med 2006;47:223\u201333.","journal-title":"J Nucl Med"},{"key":"2342_CR89","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1210\/jc.86.2.895","volume":"86","author":"G Kaltsas","year":"2001","unstructured":"Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL, et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 2001;86:895\u2013902.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2342_CR90","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1055\/s-0038-1632205","volume":"38","author":"S Hoegerle","year":"1999","unstructured":"Hoegerle S, Schneider B, Kraft A, Moser E, Nitzsche EU. Imaging of a metastatic gastrointestinal carcinoid by F-18-DOPA positron emission tomography. Nuklearmedizin 1999;38(4):127\u201330.","journal-title":"Nuklearmedizin"},{"key":"2342_CR91","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1148\/radiology.220.2.r01au25373","volume":"220","author":"S Hoegerle","year":"2001","unstructured":"Hoegerle S, Altehoefer C, Ghanem N, Koehler G, Waller CF, Scheruebl H, et al. Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology 2001;220:373\u201380.","journal-title":"Radiology"},{"issue":"4","key":"2342_CR92","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s002590100475","volume":"28","author":"C Rest Le","year":"2001","unstructured":"Le Rest C, Bomanji JB, Costa DC, Townsend CE, Visvikis D, Ell PJ. Functional imaging of malignant paragangliomas and carcinoid tumours. Eur J Nucl Med 2001;28(4):478\u201382.","journal-title":"Eur J Nucl Med"},{"key":"2342_CR93","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/00006231-200208000-00005","volume":"23","author":"T Belhocine","year":"2002","unstructured":"Belhocine T, Foidart J, Rigo P, Najjar F, Thiry A, Quatresooz P, et al. Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67. Nucl Med Commun 2002;23:727\u201334.","journal-title":"Nucl Med Commun"},{"issue":"13","key":"2342_CR94","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.ejca.2009.04.037","volume":"45","author":"HB Fiebrich","year":"2009","unstructured":"Fiebrich HB, Brouwers AH, Koopmans KP, de Vries EG. Combining 6-fluoro-[18F]l-dihydroxyphenylalanine and [18F]fluoro-2-deoxy-d-glucose positron emission tomography for distinction of non-carcinoid malignancies in carcinoid patients. Eur J Cancer 2009;45(13):2312\u20135.","journal-title":"Eur J Cancer"},{"issue":"3","key":"2342_CR95","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1530\/ERC-11-0392","volume":"19","author":"S Amin","year":"2012","unstructured":"Amin S, Warner RR, Itzkowitz SH, Kim MK. The risk of metachronous cancers in patients with small-intestinal carcinoid tumors: a US population-based study. Endocr Relat Cancer 2012;19(3):381\u20137.","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"2342_CR96","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1007\/s00259-011-1862-5","volume":"38","author":"HB Fiebrich","year":"2011","unstructured":"Fiebrich HB, de Jong JR, Kema IP, Koopmans KP, Sluiter W, Dierckx RA, et al. Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour. Eur J Nucl Med Mol Imaging 2011;38(10):1854\u201361.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"2342_CR97","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00259-008-1030-8","volume":"36","author":"A Haug","year":"2009","unstructured":"Haug A, Auernhammer CJ, W\u00e4ngler B, Tiling R, Schmidt G, G\u00f6ke B, et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2009;36(5):765\u201370.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"S2","key":"2342_CR98","first-page":"S302","volume":"37","author":"F Montravers","year":"2010","unstructured":"Montravers F, Nataf V, Balogova S, Calzada M, Maurel G, Kerrou K, et al. Comparison of FDOPA (18F) and DOTATOC (68Ga) PET\/CT for detection of ileal carcinoid tumours. Eur J Nucl Med Mol Imaging 2010;37(S2):S302. abstract OP586.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"2342_CR99","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/MNM.0b013e32834f2603","volume":"33","author":"VN Yakemchuk","year":"2012","unstructured":"Yakemchuk VN, Jager PL, Chirakal R, Reid R, Major P, Gulenchyn KY. PET\/CT using 18F-FDOPA provides improved staging of carcinoid tumor patients in a Canadian setting. Nucl Med Commun 2012;33(3):322\u201330.","journal-title":"Nucl Med Commun"},{"issue":"1","key":"2342_CR100","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.27716","volume":"119","author":"A Dolcetta-Capuzzo","year":"2013","unstructured":"Dolcetta-Capuzzo A, Villa V, Albarello L, Franchi GM, Gemma M, Scavini M, et al. Gastroenteric neuroendocrine neoplasms classification: comparison of prognostic models. Cancer 2013;119(1):36\u201344.","journal-title":"Cancer"},{"issue":"9","key":"2342_CR101","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/RLU.0b013e31818130c5","volume":"33","author":"K Jones","year":"2008","unstructured":"Jones K, Subramaniam RM, Durnick DK, Peller PJ. F-18-FDG-PET\/CT imaging of small cell carcinoma of the colon. Clin Nucl Med 2008;33(9):645\u20136.","journal-title":"Clin Nucl Med"},{"issue":"Suppl 1","key":"2342_CR102","doi-asserted-by":"crossref","first-page":"S169","DOI":"10.1007\/s12032-010-9674-1","volume":"28","author":"DG Power","year":"2011","unstructured":"Power DG, Asmis TR, Tang LH, Brown K, Kemeny NE. High-grade neuroendocrine carcinoma of the colon, long-term survival in advanced disease. Med Oncol 2011;28 Suppl 1:S169\u201374.","journal-title":"Med Oncol"},{"key":"2342_CR103","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1148\/radiology.195.2.7724749","volume":"195","author":"H Ahlstr\u00f6m","year":"1995","unstructured":"Ahlstr\u00f6m H, Eriksson B, Bergstr\u00f6m M, Bjurling P, L\u00e5ngstr\u00f6m B, Oberg K. Pancreatic neuroendocrine tumors: diagnosis with PET. Radiology 1995;195:333\u20137.","journal-title":"Radiology"},{"issue":"7","key":"2342_CR104","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.2967\/jnumed.110.085142","volume":"52","author":"D Wild","year":"2011","unstructured":"Wild D, Christ E, Caplin ME, Kurzawinski TR, Forrer F, Br\u00e4ndle M, et al. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med 2011;52(7):1073\u20138.","journal-title":"J Nucl Med"},{"key":"2342_CR105","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1210\/jc.2006-1479","volume":"92","author":"S Kauhanen","year":"2007","unstructured":"Kauhanen S, Sepp\u00e4nen M, Minn H, Gullichsen R, Salonen A, Alanen K, et al. Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or \u03b2-cell hyperplasia in adult patients. J Clin Endocrinol Metab 2007;92:1237\u201344.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2342_CR106","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1210\/jc.2009-1357","volume":"95","author":"L Tessonnier","year":"2010","unstructured":"Tessonnier L, Sebag F, Ghander C, De Micco C, Reynaud R, Palazzo FF, et al. Limited value of 18F-F-DOPA PET to localize pancreatic insulin-secreting tumors in adults with hyperinsulinemic hypoglycemia. J Clin Endocrinol Metab 2010;95(1):303\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2342_CR107","first-page":"68","volume":"54","author":"D Putzer","year":"2010","unstructured":"Putzer D, Gabriel M, Kendler D, Henninger B, Knoflach M, Kroiss A, et al. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. Q J Nucl Med Mol Imaging 2010;54(1):68\u201375.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"3","key":"2342_CR108","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1210\/jc.2010-2022","volume":"96","author":"R Abgral","year":"2011","unstructured":"Abgral R, Leboulleux S, D\u00e9andreis D, Aup\u00e9rin A, Lumbroso J, Dromain C, et al. Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (\u226510\u00a0%) well-differentiated endocrine carcinoma staging. J Clin Endocrinol Metab 2011;96(3):665\u201371.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2342_CR109","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1007\/s00259-007-0498-y","volume":"34","author":"MJ Ribeiro","year":"2007","unstructured":"Ribeiro MJ, Boddaert N, Bellann\u00e9-Chantelot C, Bourgeois S, Valayannopoulos V, Delzescaux T, et al. The added value of [18F]fluoro-L-DOPA PET in the diagnosis of hyperinsulinism of infancy: a retrospective study involving 49 children. Eur J Nucl Med Mol Imaging 2007;34(12):2120\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2342_CR110","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2337\/diabetes.55.01.06.db05-1128","volume":"55","author":"T Otonkoski","year":"2006","unstructured":"Otonkoski T, N\u00e4nt\u00f6-Salonen K, Sepp\u00e4nen M, Veijola R, Huopio H, Hussain K, et al. Noninvasive diagnosis of focal hyperinsulinism of infancy with [18F]-DOPA positron emission tomography. Diabetes 2006;55:13\u20138.","journal-title":"Diabetes"},{"key":"2342_CR111","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1210\/jc.2007-1637","volume":"92","author":"OT Hardy","year":"2007","unstructured":"Hardy OT, Hernandez-Pampaloni M, Saffer JR, Sheuermann JS, Ernst LM, Freifelder R, et al. Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism. J Clin Endocrinol Metab 2007;92:4706\u201311.","journal-title":"J Clin Endocrinol Metab"},{"key":"2342_CR112","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1148\/radiol.2532081445","volume":"253","author":"C Capito","year":"2009","unstructured":"Capito C, Khen-Dunlop N, Ribeiro MJ, Brunelle F, Aigrain Y, Cr\u00e9tolle C, et al. Value of 18F-fluoro-L-dopa PET in the preoperative localization of focal lesions in congenital hyperinsulinism. Radiology 2009;253:216\u201322.","journal-title":"Radiology"},{"issue":"1","key":"2342_CR113","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jpedsurg.2010.09.093","volume":"46","author":"A Zani","year":"2011","unstructured":"Zani A, Nah SA, Ron O, Totonelli G, Ismail D, Smith VV, et al. The predictive value of preoperative fluorine-18-L-3,4-dihydroxyphenylalanine positron emission tomography-computed tomography scans in children with congenital hyperinsulinism of infancy. J Pediatr Surg 2011;46(1):204\u20138.","journal-title":"J Pediatr Surg"},{"issue":"1","key":"2342_CR114","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1053\/j.sempedsurg.2010.10.007","volume":"20","author":"W Mohnike","year":"2011","unstructured":"Mohnike W, Barthlen W, Mohnike K, Blankenstein O. Positron emission tomography\/computed tomography diagnostics by means of fluorine-18-L-dihydroxyphenylalanine in congenital hyperinsulinism. Semin Pediatr Surg 2011;20(1):23\u20137.","journal-title":"Semin Pediatr Surg"},{"issue":"11","key":"2342_CR115","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1007\/s00247-012-2459-2","volume":"42","author":"G Treglia","year":"2012","unstructured":"Treglia G, Mirk P, Giordano A, Rufini V. Diagnostic performance of fluorine-18-dihydroxyphenylalanine positron emission tomography in diagnosing and localizing the focal form of congenital hyperinsulinism: a meta-analysis. Pediatr Radiol 2012;42(11):1372\u20139.","journal-title":"Pediatr Radiol"},{"key":"2342_CR116","doi-asserted-by":"crossref","unstructured":"Blomberg BA, Moghbel MC, Saboury B, Stanley CA, Alavi A. The value of radiologic interventions and (18)F-DOPA PET in diagnosing and localizing focal congenital hyperinsulinism: systematic review and meta-analysis. Mol Imaging Biol 2013;15:97\u2013105.","DOI":"10.1007\/s11307-012-0572-0"},{"issue":"8","key":"2342_CR117","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/01.rlu.0000227363.96010.0c","volume":"31","author":"A Iagaru","year":"2006","unstructured":"Iagaru A, Gamie S, Segall G. F-18 FDG PET imaging of urinary bladder oat cell carcinoma with widespread osseous metastases. Clin Nucl Med 2006;31(8):476\u20138.","journal-title":"Clin Nucl Med"},{"issue":"6","key":"2342_CR118","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1440-1843.2007.01161.x","volume":"12","author":"T Fujishita","year":"2007","unstructured":"Fujishita T, Kishida M, Taki H, Shinoda C, Miyabayashi K, Fujishita M, et al. Detection of primary and metastatic lesions by [18F]fluoro-2-deoxy-D-glucose PET in a patient with thymic carcinoid. Respirology 2007;12(6):928\u201330.","journal-title":"Respirology"},{"issue":"21","key":"2342_CR119","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.2169\/internalmedicine.48.2407","volume":"48","author":"Y Kobashi","year":"2009","unstructured":"Kobashi Y, Shimizu H, Mouri K, Irei T, Oka M. Clinical usefulness of fluoro-2-deoxy-D-glucose PET in a case with multiple bone metastases of carcinoid tumor after ten years. Intern Med 2009;48(21):1919\u201323.","journal-title":"Intern Med"},{"issue":"6","key":"2342_CR120","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1510\/icvts.2010.237651","volume":"11","author":"R Dutta","year":"2010","unstructured":"Dutta R, Kumar A, Julka PK, Mathur SR, Kaushal S, Kumar R, et al. Thymic neuroendocrine tumour (carcinoid): clinicopathological features of four patients with different presentation. Interact Cardiovasc Thorac Surg 2010;11(6):732\u20136.","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"1","key":"2342_CR121","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00003072-200201000-00003","volume":"27","author":"ME Spieth","year":"2002","unstructured":"Spieth ME, Lin YG, Nguyen TT. Diagnosing and treating small-cell carcinomas of prostatic origin. Clin Nucl Med 2002;27(1):11\u20137.","journal-title":"Clin Nucl Med"},{"key":"2342_CR122","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1200\/JCO.2007.14.5409","volume":"26","author":"CJ Anker","year":"2008","unstructured":"Anker CJ, Dechet C, Isaac JC, Akerley W, Shrieve DC. Small-cell carcinoma of the prostate. J Clin Oncol 2008;26:1168\u201371.","journal-title":"J Clin Oncol"},{"key":"2342_CR123","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/RLU.0b013e3181b06aed","volume":"34","author":"M Yilmaz","year":"2009","unstructured":"Yilmaz M, Celen Z, Sevinc A, Karakok M. Widespread metastases in small cell carcinoma of the prostate on FDG PET\/CT. Clin Nucl Med 2009;34:598\u2013600.","journal-title":"Clin Nucl Med"},{"key":"2342_CR124","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/RLU.0b013e3181db4ce9","volume":"35","author":"R Carvalho Flamini de","year":"2010","unstructured":"de Carvalho Flamini R, Yamaga L, Mello ME, Wagner J, Livorsi Da Cunha M, Osawa A, et al. F-18 FDG PET\/CT imaging in small cell prostate cancer. Clin Nucl Med 2010;35:452\u20133.","journal-title":"Clin Nucl Med"},{"issue":"6","key":"2342_CR125","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s10147-011-0198-2","volume":"16","author":"JE Brammer","year":"2011","unstructured":"Brammer JE, Lulla P, Lynch GR. Complete remission in a patient with metastatic mixed adenocarcinoma\/extrapulmonary small cell carcinoma of the prostate. Int J Clin Oncol 2011;16(6):722\u20135.","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"2342_CR126","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10620-011-1854-0","volume":"57","author":"MD Miljkovi\u0107","year":"2012","unstructured":"Miljkovi\u0107 MD, Girotra M, Abraham RR, Erlich RB. Novel medical therapies of recurrent and metastatic gastroenteropancreatic neuroendocrine tumors. Dig Dis Sci 2012;57(1):9\u201318.","journal-title":"Dig Dis Sci"},{"issue":"6","key":"2342_CR127","doi-asserted-by":"crossref","first-page":"858","DOI":"10.2967\/jnumed.108.057505","volume":"50","author":"E Garin","year":"2009","unstructured":"Garin E, Le Jeune F, Devillers A, Cuggia M, de Lajarte-Thirouard AS, Bouriel C, et al. Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med 2009;50(6):858\u201364.","journal-title":"J Nucl Med"},{"issue":"3","key":"2342_CR128","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/PAS.0b013e318158a397","volume":"32","author":"AM Schmitt","year":"2008","unstructured":"Schmitt AM, Riniker F, Anlauf M, Schmid S, Soltermann A, Moch H, et al. Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases. Am J Surg Pathol 2008;32(3):420\u20135.","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"2342_CR129","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/PAS.0b013e31824aba59","volume":"36","author":"ES Chan","year":"2012","unstructured":"Chan ES, Alexander J, Swanson PE, Jain D, Yeh MM. PDX-1, CDX-2, TTF-1, and CK7: a reliable immunohistochemical panel for pancreatic neuroendocrine neoplasms. Am J Surg Pathol 2012;36(5):737\u201343.","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"2342_CR130","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1097\/SLA.0b013e3181fd37e8","volume":"252","author":"A Frilling","year":"2010","unstructured":"Frilling A, Sotiropoulos GC, Radtke A, Malago M, Bockisch A, Kuehl H, et al. The impact of 68Ga-DOTATOC positron emission tomography\/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg 2010;252(5):850\u20136.","journal-title":"Ann Surg"},{"issue":"1","key":"2342_CR131","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00259-009-1205-y","volume":"37","author":"V Prasad","year":"2010","unstructured":"Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET\/CT. Eur J Nucl Med Mol Imaging 2010;37(1):67\u201377.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"2342_CR132","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/RLU.0b013e31823ea730","volume":"37","author":"N Naswa","year":"2012","unstructured":"Naswa N, Sharma P, Kumar A, Soundararajan R, Kumar R, Malhotra A, et al. 68Ga-DOTANOC PET\/CT in patients with carcinoma of unknown primary of neuroendocrine origin. Clin Nucl Med 2012;37(3):245\u201351.","journal-title":"Clin Nucl Med"},{"issue":"9","key":"2342_CR133","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1055\/s-0031-1284368","volume":"119","author":"N Perakakis","year":"2011","unstructured":"Perakakis N, Laubner K, Keck T, Steffl D, Lausch M, Meyer PT, et al. Ectopic ACTH-syndrome due to a neuroendocrine tumour of the appendix. Exp Clin Endocrinol Diabetes 2011;119(9):525\u20139.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"9","key":"2342_CR134","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/RLU.0b013e318262adc7","volume":"37","author":"C Schalin-J\u00e4ntti","year":"2012","unstructured":"Schalin-J\u00e4ntti C, Ahonen A, Sepp\u00e4nen M. 18F-DOPA PET\/CT but not 68Ga-DOTA-TOC PET\/CT revealed the underlying cause of ectopic Cushing syndrome. Clin Nucl Med 2012;37(9):904\u20135.","journal-title":"Clin Nucl Med"},{"issue":"4","key":"2342_CR135","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1530\/eje.1.01839","volume":"152","author":"A Markou","year":"2005","unstructured":"Markou A, Manning P, Kaya B, Datta SN, Bomanji JB, Conway GS. [18F]fluoro-2-deoxy-D-glucose ([18F]FDG) positron emission tomography imaging of thymic carcinoid tumor presenting with recurrent Cushing\u2019s syndrome. Eur J Endocrinol 2005;152(4):521\u20135.","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2342_CR136","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.revmed.2008.01.007","volume":"29","author":"E Gomard-Mennesson","year":"2008","unstructured":"Gomard-Mennesson E, S\u00e8ve P, De La Roche E, Collardeau-Frachon S, Lombard-Bohas C, Broussolle C. Thymic carcinoid tumor revealed by a\u2009Cushings\u2019 syndrome: usefulness of positron emission tomography. Rev Med Interne 2008;29(9):751\u20133.","journal-title":"Rev Med Interne"},{"issue":"4","key":"2342_CR137","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/BF03346308","volume":"30","author":"NA Shah","year":"2007","unstructured":"Shah NA, Urusova IA, D\u2019Agnolo A, Colquhoun SD, Rosenbloom BE, Vener SL, et al. Primary hepatic carcinoid tumor presenting as Cushing\u2019s syndrome. J Endocrinol Invest 2007;30(4):327\u201333.","journal-title":"J Endocrinol Invest"},{"issue":"11","key":"2342_CR138","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/BF03350344","volume":"33","author":"A Nikolaou","year":"2010","unstructured":"Nikolaou A, Thomas D, Kampanellou C, Alexandraki K, Andersson LG, Sundin A, et al. The value of 11C-5-hydroxy-tryptophan positron emission tomography in neuroendocrine tumor diagnosis and management: experience from one center. J Endocrinol Invest 2010;33(11):794\u20139.","journal-title":"J Endocrinol Invest"},{"issue":"8","key":"2342_CR139","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1055\/s-0029-1243634","volume":"118","author":"J Singer","year":"2010","unstructured":"Singer J, Werner F, Koch CA, Bartels M, Aigner T, Lincke T, et al. Ectopic Cushing\u2019s syndrome caused by a well differentiated ACTH-secreting neuroendocrine carcinoma of the ileum. Exp Clin Endocrinol Diabetes 2010;118(8):524\u20139.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"2","key":"2342_CR140","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1055\/s-0031-1297967","volume":"120","author":"MJ Willhauck","year":"2012","unstructured":"Willhauck MJ, P\u00f6pperl G, Rachinger W, Giese A, Auernhammer CJ, Spitzweg C. An unusual case of ectopic ACTH syndrome. Exp Clin Endocrinol Diabetes 2012;120(2):63\u20137.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"3","key":"2342_CR141","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1210\/jc.2009-2282","volume":"95","author":"MS Zemskova","year":"2010","unstructured":"Zemskova MS, Gundabolu B, Sinaii N, Chen CC, Carrasquillo JA, Whatley M, et al. Utility of various functional and anatomic imaging modalities for detection of ectopic adrenocorticotropin-secreting tumors. J Clin Endocrinol Metab 2010;95(3):1207\u201319.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2342_CR142","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1055\/s-0038-1625218","volume":"45","author":"A Lange-Nolde","year":"2006","unstructured":"Lange-Nolde A, Zajic T, Slawik M, Brink I, Reincke M, Moser E, et al. PET with 18F-DOPA in the imaging of parathyroid adenoma in patients with primary hyperparathyroidism. A pilot study. Nuklearmedizin 2006;45(5):193\u20136.","journal-title":"Nuklearmedizin"},{"issue":"9","key":"2342_CR143","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s12149-012-0634-z","volume":"26","author":"V Froeling","year":"2012","unstructured":"Froeling V, Elgeti F, Maurer MH, Scheurig-Muenkler C, Beck A, Kroencke TJ, et al. Impact of Ga-68 DOTATOC PET\/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia. Ann Nucl Med 2012;26(9):738\u201343.","journal-title":"Ann Nucl Med"},{"issue":"2","key":"2342_CR144","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1210\/jc.2002-021354","volume":"88","author":"L Gourgiotis","year":"2003","unstructured":"Gourgiotis L, Sarlis NJ, Reynolds JC, VanWaes C, Merino MJ, Pacak K. Localization of medullary thyroid carcinoma metastasis in a multiple endocrine neoplasia type 2A patient by 6-[18F]-fluorodopamine positron emission tomography. J Clin Endocrinol Metab 2003;88(2):637\u201341.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2342_CR145","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S0748-7983(03)00137-9","volume":"29","author":"A Bo\u00e9r","year":"2003","unstructured":"Bo\u00e9r A, Szak\u00e1ll Jr S, Klein I, K\u00e1sler M, Vincze B, Tr\u00f3n L, et al. FDG PET imaging in hereditary thyroid cancer. Eur J Surg Oncol 2003;29(10):922\u20138.","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"2342_CR146","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/MNM.0b013e3283384587","volume":"31","author":"E Skoura","year":"2010","unstructured":"Skoura E, Rondogianni P, Alevizaki M, Tzanela M, Tsagarakis S, Piaditis G, et al. Role of [(18)F]FDG-PET\/CT in the detection of occult recurrent medullary thyroid cancer. Nucl Med Commun 2010;31(6):567\u201375.","journal-title":"Nucl Med Commun"},{"issue":"5","key":"2342_CR147","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/bjs.6937","volume":"97","author":"M Schiesser","year":"2010","unstructured":"Schiesser M, Veit-Haibach P, Muller MK, Weber M, Bauerfeind P, Hany T, et al. Value of combined 6-[18F]fluorodihydroxyphenylalanine PET\/CT for imaging of neuroendocrine tumours. Br J Surg 2010;97(5):691\u20137.","journal-title":"Br J Surg"},{"issue":"4","key":"2342_CR148","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2967\/jnumed.106.035667","volume":"48","author":"M Gabriel","year":"2007","unstructured":"Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48(4):508\u201318.","journal-title":"J Nucl Med"},{"issue":"11","key":"2342_CR149","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.2967\/jnumed.111.101675","volume":"53","author":"AR Haug","year":"2012","unstructured":"Haug AR, Cindea-Drimus R, Auernhammer CJ, Reincke M, W\u00e4ngler B, Uebleis C, et al. The role of 68Ga-DOTATATE PET\/CT in suspected neuroendocrine tumors. J Nucl Med 2012;53(11):1686\u201392.","journal-title":"J Nucl Med"},{"issue":"2","key":"2342_CR150","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-2036.1999.00466.x","volume":"13","author":"S Sanduleanu","year":"1999","unstructured":"Sanduleanu S, Stridsberg M, Jonkers D, Hameeteman W, Biemond I, Lundqvist G, et al. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case\u2013control study. Aliment Pharmacol Ther 1999;13(2):145\u201353.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"2342_CR151","doi-asserted-by":"crossref","first-page":"E1731","DOI":"10.1210\/jc.2012-1548","volume":"97","author":"HH Mosli","year":"2012","unstructured":"Mosli HH, Dennis A, Kocha W, Asher LJ, Van Uum SH. Effect of short-term proton pump inhibitor treatment and its discontinuation on chromogranin A in healthy subjects. J Clin Endocrinol Metab 2012;97(9):E1731\u20135.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2342_CR152","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/MPA.0b013e318243a0b6","volume":"41","author":"D Raines","year":"2012","unstructured":"Raines D, Chester M, Diebold AE, Mamikunian P, Anthony CT, Mamikunian G, et al. A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans. Pancreas 2012;41(4):508\u201311.","journal-title":"Pancreas"},{"issue":"8 Pt 1","key":"2342_CR153","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1093\/clinchem\/36.8.1519","volume":"36","author":"DW Mercer","year":"1990","unstructured":"Mercer DW, Virji MA, Barry GE, Piper ML. New solid-phase enzyme immunoassay of neuron-specific enolase in serum: effect of storage temperature, lipemia, icterus, and hemolysis. Clin Chem 1990;36(8 Pt 1):1519.","journal-title":"Clin Chem"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-013-2342-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-013-2342-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-013-2342-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T20:37:31Z","timestamp":1644352651000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-013-2342-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,16]]},"references-count":153,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["2342"],"URL":"https:\/\/doi.org\/10.1007\/s00259-013-2342-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,16]]}}}